RAPT Therapeutics: Promising Clinical Developments and Strong Financial Performance Justify Buy Rating

Wells Fargo analyst Yanan Zhu maintained a Buy rating on RAPT Therapeutics (RAPT – Research Report) yesterday and set a price target of $6.00.

Yanan Zhu has given his Buy rating due to a combination of factors including RAPT Therapeutics’ promising clinical developments and financial performance. The company is on track to initiate a Phase 2b trial for RPT904 in food allergy by the second half of 2025, which is a significant milestone that could potentially enhance its market position. Additionally, RAPT’s collaboration with Jemincare is expected to yield important clinical data for RPT904 in chronic spontaneous urticaria (CSU) later this year, which will guide further development strategies.
Moreover, RAPT Therapeutics reported better-than-expected financial results for the first quarter of 2025, with a net loss per share of $0.08 compared to the consensus estimate of $0.14. The company maintains a strong cash position of approximately $179 million, which supports its ability to reach multiple clinical milestones, including the anticipated Phase 2b food allergy data. These factors collectively underpin Yanan Zhu’s optimistic outlook on RAPT’s potential for growth and success, justifying the Buy rating.